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β-Cryptoxanthin, a carotenoid, and hesperidin, a ﬂavonoid, possess inhibitory eﬀects on carcinogenesis in several tissues. We
recently have prepared a pulp (CHRP) and citrus juices (MJ2 and MJ5) from a satsuma mandarin (Citrus unshiu Mar.) juice (MJ).
They contain high amounts of β-cryptoxanthin and hesperidin. We have demonstrated that CHRP and/or MJs inhibit chemically
inducedratcolon,rattongue,andmouselungtumorigenesis.GavagewithCHRPresultedinanincreaseofactivitiesofdetoxifying
enzymesintheliver,colon,andtonguerats’.CHRPandMJswerealsoabletosuppresstheexpressionofproinﬂammatorycytokines
and inﬂammatory enzymes in the target tissues. This paper describes the ﬁndings of our in vivo preclinical experiments to develop
a strategy for cancer chemoprevention of colon, tongue, and lung neoplasms by use of CHRP and MJs.
1.Introduction
Epithelial malignant neoplasms remain a major health chal-
lenge in the world. Despite improvements in staging and the
application and integration of therapies, including surgery,
radiotherapy, and chemotherapy, the 5-year survival rate for
individuals with malignancies is still low. Even if strategies
for early detection are successful and malignancies are de-
tected at a stage where local tumor resection and treatment
is curative, the patients will still have signiﬁcant risk for
developing second primary malignancy associated with the
problem, including “ﬁeld cancerization” [1–6]. For this rea-
son,itisimportanttofocusonchemopreventivestrategiesto
prevent the development of epithelial malignancies [5, 6].
Cancer prevention is a rapidly expanding discipline that
focuses on the discovery and identiﬁcation of dietary agents
and drugs that prevent or inhibit epithelial malignant tumor
development [5–8]. Since approximately one-third of the
overall risk of cancer is attributable to diet, a large number
of dietary compounds have been tested to determine their
chemopreventive ability using animal carcinogenesis models
[4,9–12]. It is known that certaincarotenoids and ﬂavonoids
can inhibit cancer development in animal carcinogenesis
models [4, 10–12]. β-Cryptoxanthin, (Figure 1(a)), a caro-
tenoid, and hesperidin (Figure 1(b)), a ﬂavonoid, are such
compounds.β-Cryptoxanthinwithnonsubstitutedβ-ionone
cyclesand provitamin A property possesses severalbiological
activities including scavenging of free radicals, enhancement
of gap junctions, immunomodulation, and regulation of
enzyme activity involved in carcinogenesis [13, 14]. β-Cryp-
toxanthin is reported to inhibit mouse skin tumorigenesis
[15]andratcoloncarcinogenesis[16].Hesperidin,presentin
several vegetables and fruits, has antioxidant property, anti-
inﬂammatory eﬀect, and inhibiting eﬀect on prostaglandin
biosynthesis. This ﬂavonoid inhibits chemically induced car-
cinogenesis in several organs [4, 10–12]. β-Cryptoxanthin
and hesperidin are thus considered to be potential cancer
chemopreventive compounds. However, edible plants con-
tain only small amounts of these chemicals. To obtain high-
er contents of these compounds in foods, therefore, we pre-
paredapulp(CHRP)containinghighamountsofβ-cryptox-
anthin and hesperidin during the process of making satsuma2 Journal of Biomedicine and Biotechnology
(a)
(b)
Figure 1: 3D chemical structures of (a) β-cryptoxanthin and (b)
hesperidin.
mandarin (Citrus unshiu Marc.) juice (MJ). CHRP (100g)
contained 0.67g β-cryptoxanthin and 3.58g hesperidin: the
contents of β-cryptoxanthin and hesperidin are 583 times
and 38 times greater than those in edible parts of satsuma
mandarin (Citrus unshiu Marc.), respectively. In addition,
we prepared Satsuma mandarin (Citrus unshiu Marc.) juices,
called MJ2 (1.7mg β-cryptoxanthin and 84mg hesperi-
din/100g) and MJ5 (84mg β-cryptoxanthin and 100mg
hesperidin/100g), by adding CHRP to usual mandarin or-
ange juice (MJ: 0.8mg β-cryptoxanthin and 79mg hesperi-
din/100g).
We describe the chemopreventive eﬀects of CHRP and
MJs on chemically induced oncogenesis in the colon and
tongue of rats and mouse lung [17–19].
2.DietaryCHRPInhibitsChemicallyInduced
RatColon Carcinogenesis
To predict possible inhibitory action of CHRP in colon car-
cinogenesis,theeﬀectsofCHRPonthedevelopmentofaber-
rant crypt foci (ACF), which are putative precursor lesions of
colonic adenocarcinoma (ADC) of rodents and human [20–
22], were examined in rats initiated with a colon carcinogen,
azoxymethane(AOM)[17].Atotalof32maleF344ratswere
used in the study. Animals were divided into the AOM alone,
AOM and 500ppm HCRP, 500ppm HCRP, and untreated
groups. Rats were initiated with AOM by two weekly sub-
cutaneous injections (20mg/kgbw) and were fed the diets
containing CHRP at 500ppm for 4 weeks (initiation stage),
starting one week before the ﬁrst dose of AOM. At week
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Figure 2: Dietary CHRP suppresses AOM-induced colonic aber-
rant crypt foci (ACF) in rats.
11 of the experimental week, the frequency of ACF was
determined. As illustrated in Figure 2, all rats in the AOM-
alone group developed ACF with a frequency of 119 ± 5
ACF per rat, while rats in the AOM + 500ppm CHRP group
had a frequency of 97 ± 11 (P<0.05). The CHRP-alone
and untreated groups did not develop ACF. Immunohisto-
chemical analysis of proliferation activity, proliferating-cell-
nuclear-antigen- (PCNA-) positive index, was done, since
promising chemopreventive compounds act through mod-
ulation of cell proliferative activity in the target organs [11,
23]. As presented in Figure 2, the PCNA-labeling index in
ACF was signiﬁcantly decreased by feeding with the CHIRP
diet (P<0.05).
Based on the ﬁndings from this preliminary experiment,
a long-term animal experiment was conducted to deter-
mine the suppressing eﬀects of CHRP on the development
of colonic ADC induced by AOM. A total of 69 rats were
randomly divided into 5 groups, namely, the AOM alone,
AOM + 500ppm CHRP for 4 weeks of the initiation stage,
AOM → 500ppm CHRP, for 28 weeks of the promotion
stage, 500ppm CHRP for the entire experimental period (32
weeks), and untreated groups. Animals were initiated with
threeweeklysubcutaneousinjectionsofAOM(15mg/kgbw)
to induce colonic neoplasms. As given in Figure 3, the
frequencies of colonic ADC in the AOM + 500ppm CHRP
group (47%) and the AOM → 500ppm CHRP group (21%,
P<0.05) were smaller than in group 1 (60%). In Figure 3,
the PCNA-labeling indices of large bowel ADC developed in
the the AOM + 500ppm CHRP group and the AOM →
500ppm CHRP group were signiﬁcantly smaller than the
AOM alone group (P<0.05).Journal of Biomedicine and Biotechnology 3
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Figure 3: Dietary CHRP inhibits AOM-induced colonic adenocar-
cinoma (ADC) in rats.
3. Supplementationwith CHRPinDiet
Inhibits4-Nitroquinoline-1-Oxide-(4-NQO-)
InducedRat Tongue Carcinogenesis
Oral cancer is an important public health issue because
its occurrence is strongly associated with cigarette smoking
and alcohol drinking [2, 3, 24]. Oral cancer is one of the
ten most frequent cancers worldwide, with three-quarter of
all cases occurring in the developing countries [2, 3]. It
varies in the frequency greatly among diﬀerent countries and
geographic regions [2, 3]. The incidence and mortality of
oral cancer have increased over the past decades in Europe
[25]andintheUnitedStates[26].Inparticular,theincidence
and mortality rate of tongue cancer, as compared to other
types of oral cancer, have increased in younger adults [27].
Chemoprevention against oral/tongue cancer development
is thus important. To determine whether CHRP can inhibit
chemically induced rat tongue carcinogenesis, a total of 67
male F344 rats were divided into 5 groups, including the
4-NQO alone group (8-week treatment with 20ppm 4-
NQO in drinking water), 4-NQO + 500ppm CHRP group
(10-week treatment during the initiation stage), 4-NQO
→ 500ppm CHRP group (22-week treatment during the
promotion stage), CHRP alone group (32-week of the entire
experiment), and untreated group. At week 32, tongue squa-
mous cell tumors (papilloma and carcinoma) and dysplasia
developed in the posterior tongue (dorsal region) of rats
that received 4-NQO. As shown in Figure 4 the incidences
of tongue squamous cell carcinoma (SCC) were 53% in
the 4-NQO alone group, 35% in the 4-NQO + 500ppm
CHRP group, and 5% in the 4-NQO → 500ppm CHRP
group. The incidence of tongue carcinoma in the 4-NQO
→ 500ppm CHRP group was signiﬁcantly smaller than
the 4-NQOO alone group (P<0.05). The multiplicity of
tongue carcinoma of this group was also lower than the 4-
NQO alone group (P<0.05). The PCNA-labeling index
of tongue SCC in the 4-NQO → 500ppm CHRP group
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Figure 4: CHRP in diet suppresses 4-NQO-induced rat tongue
squamous cell carcinoma (SCC).
was significantly smaller than the 4-NQO alone group (P<
0.05).
4.MJs, CitrusJuices Richinβ-Cryptoxanthin
andHesperidin,InhibitAOM-InducedRat
Colon Carcinogenesis
Colorectal cancer (CRC) is the fourth most common ma-
lignant neoplasm in the world [21]. Since an inverse rela-
tionship between the intake of fruits/vegetables and human
CRC has been suggested [5, 6, 28–32], primary prevention,
including chemoprevention utilizing the active compounds
in edible plants, is important for reducing this malignancy
[5, 6]. This experiment was designed to determine the
modulatory eﬀects of MJ, MJ2, and MJ5 on the occurrence
of colonic neoplasms induced by AOM in rats [19]. Also,
PCNA-labeling index in colonic neoplasms was analyzed
immunohistochemically. A total of 113 male F344 rats were
divided into 6 groups: the AOM alone group, the AOM →
MJ group, the AOM → MJ2 group, the AOM → MJ5 group,
the MJ5 alone group, and the untreated group. AOM was
giventoratbytwiceweeklysubcutaneousinjectionsatadose
level of 20mg/kg bw. MJ, MJ2, and MJ5 in black bottles were
given to rats for 12h (from 8:00 p.m. to 8:00 a.m.). Figure 5
shows the incidence and multiplicity of colonic ADC at week
38. AOM administration induced large intestinal ADC with
an incidence of 69% and a multiplicity of 0.76 ± 0.57. The
incidences and multiplicities of the AOM → MJ group, the
AOM → MJ2 group, and the AOM → MJ5 group were
signiﬁcantly smaller than the AOM alone group (P<0.05).
The mean PCNA-labeling index of adenocarcinoma in rats
of group 1 was 55 ± 7% (n = 20). The mean PCNA-
labeling indices of adenocarcinomas present in the AOM →
MJ2 and the AOM → MJ5 groups (P<0.05) were sig-
nificantly lower than the AOM alone group (55 ± 7%,
Figure 5).4 Journal of Biomedicine and Biotechnology
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Figure 5: MJs suppress AOM-induced colonic adenocarcinoma
(ADCs) in rats.
5.MJs, CitrusJuices Richinβ-Cryptoxanthin
andHesperidin,InhibitChemically Induced
Mouse LungTumorigenesis
Lung cancer is the largest cause of cancer deaths in indus-
trial countries, and cigarette smoking is regarded as the
overwhelming cause of lung cancer. Chemoprevention using
naturally occurring or synthetic compounds to arrest or
reverse the carcinogenic process is extremely important as
a lung cancer prevention strategy. 4-(Methylnitrosamino)-
1-(3-pyridyl)-1-butanone (NNK) is the most important
carcinogenic nitrosamine, because of its strong potential in
inducing lung neoplasms in rodents and its exposure to
humans through smoking [33, 34]. Using the animal model
for lung tumorigenesis with NNK, several promising agents
for prevention of lung cancers have been reported [33–38].
This experiment was aimed to determine possible modu-
latory eﬀects of MJs on the development of lung tumors
inducedbyapulmonary carcinogen,NNK,inmice[18].The
PCNA-labeling index in lung tumors was also determined.
A total of 103 male A/J mice were divided into 6 groups:
the NNK alone group, the NNK → MJ group, the NNK →
MJ2 group, the NNK → MJ5 group, the MJ5 alone group,
and the untreated group. NNK was given to mice by a single
intraperitoneal injection (10 μmol in saline/mouse). MJ,
MJ2, and MJ5 were administered to mice as a drinking water
for 21 weeks, starting one week after the NNK injection.
MJs in the black bottles were given to mice for 12hr (from
8:00 p.m. to 8:00 a.m.) At week 22, lung proliferative lesions
were diagnosed as hyperplasia and tumors, and we did not
subclassify the tumors into adenoma and adenocarcinoma,
because of the diﬃculty in evaluating malignancy [39, 40].
Pulmonary tumors (adenoma or adenocarcinoma) were
developed in all mice treated with NNK. As illustrated in
Figure 6, the incidences and the multiplicities of lung tumor
of the NNK → MJ group, the NNK → MJ2 group, and
the NNK → MJ5 group were smaller than NNK alone
group. Statistically, the incidence of lung tumors in mice
that received NNK and MJ5 was signiﬁcantly lower than the
NNK alone group (P<0.05). The multiplicities of lung
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Figure 6: MJs inhibit NNK-induced lung tumors in mice.
tumors of mice in the NNK → MJ group, the NNK →
MJ2 group, and the NNK → MJ5 group were also low, but
the diﬀerences were insigniﬁcant. The mean PCNA-labeling
indices of pulmonary tumors of the NNK → MJ group and
the NNK → MJ5 group were signiﬁcantly lower than the
NNK alone group (P<0.05, Figure 6).
6.CHRPIncreasesDetoxifyingEnzymes in
the Liver, Tongue, and Colon
Induction of enzymes that enhance the detoxiﬁcation of
chemicalcarcinogenshasbeenabroadlyeﬀectivestrategyfor
chemoprevention of experimental carcinogenesis in rodent
models. Several inducing agents are now in clinical trials
to evaluate utility for prevention of cancers associated with
unavoidable high exposures to environmental carcinogens.
Thus, certain phase II detoxifying enzyme inducers, includ-
ing phenolic antioxidants, dithiolethiones, isothiocyanates,
andtriterpenoids,areconsideredtobepromisingchemopre-
ventive in preclinical and clinical interventions [41–46].
To determine whether CHRP modiﬁes glutathione S-
tansferase (GST) and quinone reductase (QR) activities in
the liver, colon, and tongue, male F344 rats were gavaged
with CHRP at four dose levels (0, 40, 200 or 400mg/kg body
wt in 0.5mL of 5% gum Arabic) of CHRP for 5 consecutive
days [17]. Thirty min after the last gavage, the liver, colon,
and tongue were excised immediately to measure GST and
QR activities. Dosing of 40, 200, and 400mg/kg bw of CHRP
signiﬁcantly elevated liver GST (1.27-fold, 1.25-fold, and
1.50-fold increases, resp., P<0.05) and QR activities (1.24-
fold, 1.22-fold, and 1.33-fold increases, resp., P<0.05)
when compared to rats that received 0mg/kg bw. Similarly,
gavage with CHRP signiﬁcantly increased GST activity in the
colonic (1.11-fold, 1.12-fold, and 1.15-fold increases, resp.,
P<0.05)andtonguemucosa(1.33-fold,1.29-fold,and1.23-
fold increases, resp., P<0.05). CHRP treatment signiﬁcantly
increased the colonic QR activity at a dose of 400mg/kg bw
(1.13-fold increase, P<0.05) and the tongue QR activity
at doses of 200 and 400mg/kg bw (1.25-fold and 1.21-fold
increases, resp., P<0.05).Journal of Biomedicine and Biotechnology 5
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Figure 7: Dietary CHRP lowers mRNA expression of proinﬂammatory cytokines in the tongue of rats that received 4-NQO at week 8 of the
study.
7. Modulation of Cytokine Expression by
CHR PandM J sint h eT o ng ueandC o l o no f
RatsInitiatedwithCarcinogens
Chronic inﬂammation is closely associated with cancer
development [47]. Cytokines are an important group of
proteins that regulate and mediate inﬂammation and angio-
genesis. Deregulation in their production results in tumor
growth, invasion, and metastasis being facilitated. In addi-
tion to proinﬂammatory cytokines, inﬂammatory enzymes,
such as cyclooxygenase (COX)-2 and inducible nitric oxide
synthase (iNOS), are involved in carcinogenesis [48–50],
and they are good targets for cancer chemoprevention [51–
54]. The NF-E2-related factor 2 (Nrf2) is a key regulator
of the inducible expression of enzymes such as GST and
QR in catalyzing the detoxiﬁcation of reactive electrophiles
and oxidants that contribute to the formation of mutations
and ultimately cancers. Nrf2 is now recognized to regulate
a broad cytoprotective, transcriptional response leading to
prevention of damage to DNA. Nrf2 is also a good target for
cancer chemoprevention in certain tissues [55–59].
Based on these reports, we assayed mRNA expression
of tumor necrosis factor (TNF)-α, interleukin (IL)1-β,I L - 6 ,
COX-2, iNOS, and Nrf2 in the tongue and colonic mucosa
of rats to determine whether CHRP and MJs can aﬀect
this mRNA expression. Male F344 rats were initiated with
a tongue carcinogen 4-NQO (20ppm) by giving drinking
water for 8 weeks, and they were also fed diets containing
CHRP at doses of 250, 500, and 1000ppm for 8 weeks,
starting 4-NQO administration. At week 8, tongue mucosa
was scraped. In a diﬀerent experiment, male F344 rats
were initiated with a colonic carcinogen AOM by twice
weeklysubcutaneousinjections (20mg/kg bw),and theyalso
received MJ, MJ2, and MJ5 for 4 weeks from starting the
AOM injection. Colonic mucosawasscraped atweek 4 of the
experimental period. Total RNA was extracted from tongue
and colonic mucosa using the RNeasy Mini Kit (Qiagen,
Tokyo, Japan) according to the manufacturer’s protocol. The
cDNA was then synthesized from total RNA using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems Japan Ltd, Tokyo, Japan). Quantitative real-time PCR
analysis of individual cDNA was performed with ABI Prism
7500 (Applied Biosystems Japan Ltd, Tokyo, Japan) with rat
gene speciﬁc primers for TNF-α,I L - 1 β, IL-6, COX-2, and
iNOS (Applied Biosystems) on a GeneAmp 5700 Sequence
Detection System (Applied Biosystems). Fold change was
calculated using the ΔΔCt method relative to untreated
with β-actin as the endogenous control. In addition, the
speciﬁc primer (forward primer 5 -tgcccctggaagtgtcaaa-3 ,
reverse 5 -ggctgtactgtatccccagaaga-3 ) was used to measure
the expression of Nrf2. Data are illustrated in Figures 7, 8,
9,a n d10. Administration with CHRP and MJs decreased
mRNA expression of TNF-α,I L 1 - β, IL-6, COX-2, and iNOS
in the tongue and colonic mucosa, while the treatments
increased mRNA expression of Nrf2 in both mucosal tissues.
8. Discussion
We have described cancer chemopreventive ability of CHRP
and MJs in experimental animal carcinogenesis models of6 Journal of Biomedicine and Biotechnology
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Figure 8: Dietary CHRP suppresses mRNA expression of inﬂammatory enzymes, Cox-2 and iNOS, in the tongue of rats that received
4-NQO at week 8 of the study.
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Figure 9: MJs lower mRNA expression of proinﬂammatory cytokines in the colonic mucosa of rats that received AOM at week 4 of the
study.
colon, tongue, and lung cancers. Administration of CHRP
or MJs after the carcinogen exposure clearly inhibits the
development of malignant epithelial neoplasms. Miyagi et
al. [60] also reported a protective eﬀect of orange juice on
AOM-induced rat colon carcinogenesis. Our data on MJs
support their ﬁndings. The exact mechanism(s) involved in
the suppressing eﬀects of chemically induced tumorigenesis
by CHRP and MJs is not fully known. In our studies, gavage
with CHRP to rats elevated GST and QR activities in liver,
colon, and tongue. Investigations by other researchers also
demonstrated that limonin increased GST activities in sev-
eral organs including liver, colon, and lung [61]. Therefore,
it is possible that such elevation in activity of detoxifying
enzyme by CHRP treatment may contribute its chemopre-
ventiveability.Also,themodulatoryeﬀectsofCHRPandMJs
on speciﬁc species of liver CYPs, which are pertinent to the
carcinogen metabolism [38, 62, 63], should be considered,
although we did not examine their expression in our studies.
In addition, suppressing eﬀects of CHRP and MJs on hyper-
cell-proliferation activity induced by carcinogens in target
organs account for their inhibition of carcinogenesis, since
control of cell proliferation is one of the important eﬀects
of promising chemopreventive agents [23]. In our studies,
gavage with CHRP to rats elevated GST and QR activities
in liver, colon, and tongue, but strong inhibition in cancer
incidence was not found when CHRP was fed to rats during
the carcinogen treatment. This indicates that modiﬁcation of
cell proliferation of carcinoma cells rather than modiﬁcation
of activity of detoxifying enzymes may contribute to its
chemopreventiveabilitywhenthesubstancesweregivenafter
carcinogen exposure in long-term experiments.
Interesting ﬁndings in our studies are that CHRP and
MJs were able to suppress mRNA expression of several
cytokines (TNF-α,I L - 1 β, IL-6) and inﬂammatory enzymes
(COX-2 and iNOS) and enhance mRNA expression of Nrf2
in the tongue and colon of rats that received a carcinogen,Journal of Biomedicine and Biotechnology 7
Untreated
MJ5
AOM + MJ5
AOM + MJ2
A O M+M J
AOM
Cox-2
024 681 0
(a)
Untreated
MJ5
A O M+M J 5
AOM + MJ2
A O M+M J
AOM
012345
iNOS
(b)
Figure 10: MJs suppress mRNA expression of inﬂammatory enzymes, Cox-2 and iNOS, in the colonic mucosa of rats that received AOM at
week 4 of the study.
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Figure 11: Working hypothesis of the involvement of inﬂammation in multistage carcinogenesis.
4-NQO or AOM. Chronic inﬂammation is known to be
closely associated with cancer development in certain tissues
[47], including oral cavity, colon, and lung. Cytokines
regulateandmediateinﬂammationandangiogenesis.Tumor
growth, invasion, and metastasis are facilitated when there
is a deregulation in their production. Functional polymor-
phisms aﬀecting gene expression of interleukin IL-1β,4 ,- 6 ,
- 8 ,a n d- 1 0a sw e l la sT N F - α are strongly associated with
increased risk for oral cancer [64]. Recent ﬁndings also indi-
cated that interactions between cytokines and sympathetic
neurotransmitters and their respective receptors expressed
by the nerve, immune, and tumor cells appear to inﬂuence
tumorgrowth[65].Inthecolon,inﬂammatoryboweldisease
(IBD)isanimportantriskfactorforthedevelopmentofCRC
[21, 66, 67]. Inﬂammation is also likely to be involved with
other forms of sporadic as well as heritable CRC [21]. Rela-
tionshipsbetweenlunginﬂammation/injuryandlungcancer
in humans are also suggested [39]. Genetic predisposition to
chronic obstructive pulmonary disease was associated with
increased risk of developing lung cancer [68]. In addition
to proinﬂammatory cytokines, inﬂammatory enzymes, such
as COX-2 and iNOS, are involved in carcinogenesis [48–50],
and they are good targets for cancer chemoprevention [51–
54].Nrf2transcriptionfactorwasidentiﬁedinthemid-1990s
asakeyregulatoroftheinducibleexpressionofenzymessuch
as GST and QR in catalyzing the detoxiﬁcation of reactive
electrophiles and oxidants that contribute to the formation
of mutations and ultimately cancers. Nrf2 is now recognized
to regulate a broad cytoprotective, transcriptional response
leading to prevention of damage to DNA, proteins, and
lipids; recognition, repair, and removal of macromolecular
damage; and tissue renewal following toxic assaults. The
importance of this pathway as a determinant of suscepti-
bility to carcinogenesis was indicated in multiple studies
that demonstrated enhanced incidence, multiplicity, and/or
tumor burden in Nrf2-deﬁcient mice compared to wild-type
ones in models of inﬂammation and CRC and lung cancer.
Nrf2 is thus one of the targets for cancer chemoprevention
in certaintissues [55–59]. When considering the relationship
between chronic inﬂammation and cancer development
(Figure 11), such eﬀects of CHRP and MJs are attractive for
reducing tumor occurrence.8 Journal of Biomedicine and Biotechnology
Citrus fruit contains other possible chemopreventive
agents. These include d-limonene [69], auraptene [70, 71],
diosmin [72], limonin [73], and obacunone [73]. Some of
these can modify activities and expression of the detoxifying
enzymes and CYPs [74]. In addition, CHRP and MJs are able
to downregulate mRNA expression of several cytokines and
inﬂammatory enzymes and upregulate Nrf2 mRNA expres-
sion. Thus, citrus fruit is one of the rich sources of cancer
chemopreventive agents.
9. Conclusion
Our studies demonstrate that oral administration of CHRP
and MJs inhibits the development of malignant epithelial
neoplasms in colon and tongue and lung tumors of rodents
through their multiple biological functions. Further experi-
ments, including preclinical eﬃcacy and mechanistic studies
including modiﬁcation of expression of cancer-related genes
in the target tissues, are warranted to fully evaluate these nat-
ural compounds for their cancer preventive properties and
to understand their mode of action. One of the advantages
of CHRP and MJs is that, unlike synthetic chemopreventive
agents, they are natural substances present in human foods.
On the basis of our observations and knowledge of the
carcinogenic process, a strategy for cancer chemoprevention
of colon, tongue, and lung can be developed. In conclusion,
our ﬁndings may indicate that CHRP and MJs that are able
to inhibit chemically induced carcinogenesis through mod-
ulation of proliferation, detoxifying enzymes, and mRNA
expression of several cytokines and inﬂammatory enzymes
are potential cancer chemopreventive agents against tongue,
colon, and lung cancer development.
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